Refinements to the analytical testing of biosimilar candidates to verify similarity were worked into 2019 guidance from the FDA. These changes offer what the author considers a more "rational approach."
Analytical similarity assessment of biosimilar candidates is the backbone for establishing biosimilarity, a primary requirement for the licensing of biosimilars. After withdrawing its pivotal final guideline on analytical similarity testing, the FDA issued new guidance (Development of Therapeutic Protein Biosimilars: Comparative Analytical Assessment and Other Quality-Related Considerations), with many apparent and subtle differences, primarily based on my citizen petition to the FDA. For example, few people noticed that the FDA replaced “testing” with “assessment.” To assess is to test the value of something using various tools. Testing is when something is put through a series of trials to determine its value. Thus, testing is one of the ways to assess something. In this paper, I will draw attention to both substantive and subtle changes to help reduce the cost and time for the approval of biosimilars.
We have come a long way from the early days of superfluous testing of biosimilars; the new FDA guidance should be read carefully between lines; it is a more rational approach to achieving the demonstration of biosimilarity, but the FDA is like any other agency—if you keep offering to assess ad infinitum, they will have no objection to it. Manufacturers must learn the difference between “testing” and “assessment.”
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
The Growing Impact of Biosimilars in IBD Care
April 23rd 2025Biosimilars are proving to be a game-changing solution in the fight against inflammatory bowel disease (IBD), offering a cost-effective alternative to biologics with similar efficacy and safety, while innovative drug delivery systems promise to further enhance treatment outcomes and accessibility for millions worldwide.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Biosimilar and Biologic Use Increasing in Greek Patients With IBD
April 19th 2025A retrospective study from a single inflammatory bowel disease (IBD) center in Greece reported that from 2018 to 2022, the use of biologics increased by 28% yearly, and the proportion of patients using biosimilars grew from 33% to 67%.